Login to Your Account

BIO 2017

Drug pricing looms large as policymakers set their sights on biopharma

By Jennifer Boggs
Managing Editor

Thursday, June 22, 2017

SAN DIEGO – Drug pricing: Often drawing groans and sighs of resignation, those two words have managed to creep to the forefront of nearly every panel discussion as the biopharma industry gathered for the annual BIO International Convention amid increasing scrutiny by the U.S. government, expectations of an executive order from the White House – though a draft review by the New York Times indicated the latter tended more toward eliminating regulatory hurdles than actual price curbing – and the anticipated unveiling of a health care bill Thursday from Senate Republicans.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription